Moreover, NK cells of AML patients expressed the ADCC-mediating receptor CD16 at high frequencies, similarly to that of HD, without any noticeable difference between newly diagnosed and treated patients (Figure 5B, right). This evidence concerns the gene FCGR3A and acute myeloid leukemia.